Strong foreign promoters contribute to innate inflammatory responses induced by adenovirus transducing vectors.
E1-deleted adenovirus (FG Ad) transducing vectors are limited for use in vivo by their induction of strong innate and adaptive inflammatory responses. We have examined the contribution of the transgene cassette, particularly the foreign promoter driving transgene expression, in the induction of innate inflammation using a mouse ear model in which swelling is measured as a sensitive surrogate marker of the total innate inflammatory response. The commonly used cytomegalovirus major immediate early (CMV) promoter led to high-level swelling that was independent of transgene expression, while the Rous sarcoma virus and human ubiquitin C promoters led to intermediate levels of swelling and the Ad E1A promoter or no promoter led to equally low levels of swelling. Significant swelling was induced by a virus in which the E1A promoter directed pIX expression, supporting the possibility that activation of expression of Ad genes retained in the vector plays an important role in the inflammatory response. Taken together, our findings support the idea that strong foreign promoters likely play the limiting role in the induction of innate and adaptive immune responses that limit the duration of transgene expression after transduction by FG Ad vectors.
Department of Microbiology, University of Colorado Health Sciences Center, Aurora, CO 80045, USA. jerry.schaack@ucdenver.edu
Jerome
J
Schaack
Michael L
ML
Bennett
Gary S
GS
Shapiro
James
J
DeGregori
James L
JL
McManaman
John W
JW
Moorhead
D000260:Adenoviruses, Human / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity*; D000818:Animals; D004195:Disease Models, Animal; D004423:Ear / Q000473:pathology / Q000821:virology; D005260:Female; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors; D006801:Humans; D007249:Inflammation; D051379:Mice; D008807:Mice, Inbred BALB C; D011401:Promoter Regions, Genetic
Nucleic Acids Res. 1996 Feb 15;24(4):596-601
8604299
Gene Ther. 1996 Feb;3(2):137-44
8867861
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14082-7
8943064
J Biol Chem. 1992 Dec 5;267(34):24886-91
1332971
Virology. 2001 Dec 5;291(1):101-9
11878880
Virology. 2007 Dec 20;369(2):411-22
17888479
Genes Dev. 1989 Jan;3(1):49-59
2523329
Cell. 1983 Jul;33(3):695-703
6871991
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1645-50
9050832
Gene Ther. 1997 Aug;4(8):757-61
9338002
Mol Ther. 2001 May;3(5 Pt 1):697-707
11356075
Hum Gene Ther. 1999 Apr 10;10(6):965-76
10223730
Nucleic Acids Res. 1987 Oct 26;15(20):8125-48
3313277
J Virol. 2008 Nov;82(22):11167-80
18786996
Nat Genet. 1993 Dec;5(4):397-402
8298650
J Lipid Res. 2001 Mar;42(3):460-6
11254759
Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407-11
8183921
J Virol. 2004 Jun;78(11):5966-72
15140994
Viral Immunol. 2005;18(1):79-88
15802954
EMBO J. 1986 Feb;5(2):387-97
3011406
J Gene Med. 2004 Feb;6 Suppl 1:S172-83
14978760
J Immunol. 1994 Nov 15;153(10):4573-82
7963529
J Virol. 1990 Jun;64(6):2780-7
2139894
EMBO J. 1986 Jul;5(7):1633-44
3743550
Curr Top Microbiol Immunol. 2004;273:29-85
14674598
Cancer Gene Ther. 2004 Dec;11(12):819-29
15359291
J Virol. 2003 Sep;77(17):9266-77
12915542
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3124-9
14976240
Gene Ther. 1996 Nov;3(11):965-72
8940636
Hum Gene Ther. 1999 Jul 20;10(11):1773-81
10446917
Hum Gene Ther. 2007 Oct;18(10):925-36
17907966
Nucleic Acids Res. 1984 Jul 25;12(14):5589-608
6087293
J Virol. 1988 Jan;62(1):114-9
2446013
J Gen Virol. 1977 Jul;36(1):59-74
886304
J Virol. 2006 Jun;80(11):5349-60
16699015
Nature. 1984 May 3-9;309(5963):82-5
6717585
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14
9482916
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):3930-5
15753292
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7866-71
9653106
J Virol. 1983 Jun;46(3):737-48
6854739
J Virol. 1999 Feb;73(2):1046-53
9882305
Int Rev Immunol. 2004 Jan-Apr;23(1-2):75-111
14690856
Mol Ther. 2002 Apr;5(4):436-46
11945071
J Virol. 1995 Jul;69(7):4079-85
7769665